Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy

Area of Science:

• Immunology
• Cell Biology
• Rheumatology

Background:

• Chronic diseases like periodontal disease (PD) and rheumatoid arthritis (RA) involve persistent inflammation driven by immune responses.
• Proinflammatory cytokines, particularly interleukin-17 (IL-17) produced by T-helper 17 (Th17) cells, are key mediators of inflammation and autoimmune pathogenesis.

Purpose of the Study:

• To explore the role of the IL-17 signaling pathway in chronic inflammatory and autoimmune diseases.
• To investigate the potential of targeting the IL-17 receptor (IL-17R) complex as a therapeutic strategy.
• To understand the implications of IL-17 antagonism for periodontal disease progression and systemic inflammatory conditions.

Main Methods:

• Review of existing literature on Th17 cells, IL-17 cytokine, and IL-17 receptor signaling.
• Analysis of the involvement of IL-17 in localized chronic infections (PD) and systemic diseases (RA, diabetes, cardiovascular disease).
• Discussion of therapeutic approaches targeting cytokine antagonism and their clinical relevance.

Main Results:

• Th17 cells and IL-17 are critical in mediating inflammation and autoimmunity in conditions like RA and PD.
• The IL-17 receptor, composed of IL-17RA and IL-17RC subunits, is the target for IL-17's inflammatory effects.
• Current cytokine-antagonizing therapies show efficacy in RA but have limitations, highlighting the need for novel targets.

Conclusions:

• The IL-17 signaling pathway represents a promising therapeutic target for managing chronic inflammatory and autoimmune diseases.
• Targeting IL-17 may ameliorate inflammation and bone loss, with potential benefits for periodontal disease and associated systemic conditions.
• Further research is needed to fully elucidate the impact of IL-17 pathway inhibition on periodontal disease onset and progression.